Cargando…

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer

The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlack, Katrin, Krabbe, Laura-Maria, Fobker, Manfred, Schrader, Andres Jan, Semjonow, Axel, Boegemann, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037797/ https://www.ncbi.nlm.nih.gov/pubmed/27618028 http://dx.doi.org/10.3390/ijms17091520

Ejemplares similares

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
por: Boegemann, Martin, et al.
Publicado: (2016)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
por: Schlack, Katrin, et al.
Publicado: (2021)

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
por: Poteska, Renata, et al.
Publicado: (2022)

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
por: Boegemann, Martin, et al.
Publicado: (2019)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
por: Klaile, Yvonne, et al.
Publicado: (2016)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
por: James, Aloysius, et al.
Publicado: (2018)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
por: Rauch, Simon, et al.
Publicado: (2016)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
por: Katsui, Masahiro, et al.
Publicado: (2018)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Diverse monogenic subforms of human spermatogenic failure
por: Nagirnaja, Liina, et al.
Publicado: (2022)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
por: Werutsky, Gustavo, et al.
Publicado: (2019)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2014)

Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
por: Daisley, Brendan A., et al.
Publicado: (2020)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
por: Joshi, Amit, et al.
Publicado: (2020)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer †
por: Ferrero, Jean-Marc, et al.
Publicado: (2023)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
por: Nagai, Takashi, et al.
Publicado: (2018)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Abiraterone Acetate
Publicado: (2012)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
por: Campora, Sara, et al.
Publicado: (2016)

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
por: Tagawa, Scott T., et al.
Publicado: (2021)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
por: Liu, Min, et al.
Publicado: (2023)

Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
por: Chi, Kim N, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ds38uvuvjepehqd8f22k8hkemi